Topoisomerase-i activity and response to second-line chemotherapy consisting of camptothecin-11 and cisplatin in patients with ovarian cancer

International Journal of Cancer

Volumn 84, Issue 5, 1999, Pages 521-524

  Kigawa, Junzo ^a   Takahashi, Masakuni ^a   Minagawa, Yukihisa ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; DNA TOPOISOMERASE; DRUG DERIVATIVE; IRINOTECAN;

ADULT; AGED; ARTICLE; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; OVARY TUMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS;

EID: 0033595652     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0215(19991022)84:5<521::aid-ijc13>3.0.co;2-x     Document Type: Article

References (20)

1. ANDREWS, P.A. and HOWELL, S.B., Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells, 2, 35-13 (1990).
2. ANDREWS, P.A., VELURY, S., MANN, S.C. and HOWELLI, S.B., Cisdiamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res., 48, 68-73 (1988).
3. BJORNSTI, M.A., BENEDETTI, P., VIGLIANTI, G.A. and WANG, J.C., Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the anti-tumor drug camptothecin. Cancer Res., 49, 6318-6323 (1989).
4. BRADFORD, M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem.. 72, 248-254 (1976).
5. FUKUDA, M., Nismo, K., KANZAWA, R, OGASAWARA, H., ISIIIDA, T., ARIOKA, H., BOJANOWSKI, K., OKA, M. and SAIJIO, N., Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res., 56, 789-793 ( 1996).
6. GlOVANELLA, B.C., SlEHLIN, J.S., WALL, M.E., WANI, M.C., NICOLAS, A.W., Ltu, L.F., SILBER, R. and POTMESIL, M., DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science, 246, 1046-1048(1989).
7. HERTZBERG, R.P., CARANFA, M.J. and HECHT, S.M., On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry, 28, 4629-4638 (1989).
8. HÖCHSTER, H., LIEBES, L., SPEYER, J., SORICH, J., TAUBES, B., ORATZ, R., WERNZ, J., CHACHOUA, A., BLUM, R.H. and ZELENIUCHI, J.A., Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study. Clin. Cancer Res., 3, 1245-1252 (1997).
9. HSIANG, Y.H. and Liu, L.F., Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res., 48, 1722-1726(1988).
10. KlOAWA, J., MlNAGAWA, Y., ISHIHARA, H., KANAMORI, Y. and TERAKWA, N., Tumor DNA ploidy and prognosis of patients with serous cystadenocarcinoma of the ovary. Cancer, 72, 804-808 (1993).
11. Liu, L.F. and MILLER, K.G., Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerases from HeLa cell nuclei. Proc. not. Acad. Sei. (Wash.), 78, 3487-3491 (1981).
12. MlNAGAWA, Y, KlGAWA, J., IRIE, T., KANAMORI, Y, ITAMOCHI, H., CHEXG, X. and TERAKAWA, N., Enhanced topoisomerase I activity and increased topoisomerase Hot content in cisplatin-resistant cancer cell lines. Jap. J. Cancer Res., 88, 1218-1223 (1997).
13. MlNAWAGA, Y., KlGAWA, J., ISHtHARA, H., ITAMOCHI, H. and TERAKAWA, N., Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells. Jap. J. Cancer Res., 85, 966-971(1994).
14. MUGGIA, P.M., Cisplatin update. Semin. Oncol, 18, 1-4 (1991).
15. OHASHI, N., FUJIWARA, Y., YAMAOKA, N., KATOH, O., SATOW, Y. and YAMAKIDO, M., No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer. Jap. J. Cancer Res., 87, 1280-1287(1996).
16. SUBRAMANIAN, D., KRAUT, E., SiRABUS, A., YOUNG, D.C. and MULLER, M.T., Analysis of topoisomerase I/DNA complexes in patients administered topotecan. Cancer Res., 55, 2097-2103 (1995).
17. SUGIYAMA, T., YAKUSHIJI, M., NISHIDA, T., USHIJIMA, K., OKURA, N., KIGAWA, J. and TERAKAWA, N., Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer. Cancer Lett., 128, 211-218(1998).
18. TANIGUCHI, K., KOHNO, K., KAWANAMI, K., WADA, M., KANEMATSU, T. and KUWANO, M., Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins. Cancer Res., 15, 2348-2354(1996).
19. THIGPEN, J.T., VANCE, R.B. and KHANSUR, T., Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer, 15, 1559-1564(1993).
20. VAN DER ZEE, A.G J., HOLLEMA, H., DE Joxo, S., BOONSTRA, H., Gouw, A., WILLEMSE, P.H., ZULSTRA, J.G. and DE VRIES, E.G., P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/ cyclophosphamide chemotherapy. Cancer Res., 51, 5915-5920 (1991).